UNIVERSITY OF ARIZONA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1885-01-01

Employees: 10K

Market Cap: -

Website: http://www.arizona.edu

Clinical Trials

Acupuncture as Complementary Therapy for Cerebral Palsy

Phase 2

Completed

Conditions: Cerebral Palsy

Interventions: Procedure: Acupuncture

First Posted Date: 2005-09-22

Last Posted Date: 2016-05-16

Lead Sponsor: University of Arizona

Target Recruit Count: 75

Registration Number: NCT00221247

Locations: 🇨🇳
Beijing Children's Hospital, Beijing, Beijing, China
🇺🇸
The University of Arizona, Department of Pediatrics, Tucson, Arizona, United States

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Neoplasms

Interventions: Drug: bevacizumab
Drug: erlotinib

First Posted Date: 2005-08-15

Last Posted Date: 2012-05-28

Lead Sponsor: University of Arizona

Target Recruit Count: 40

Registration Number: NCT00130520

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

Not Applicable

Completed

Conditions: brca1 Mutation Carrier
brca2 Mutation Carrier
Ovarian Cancer

First Posted Date: 2004-12-09

Last Posted Date: 2010-03-24

Lead Sponsor: University of Arizona

Target Recruit Count: 40

Registration Number: NCT00098800

Locations: 🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States

Green Tea Extract (Polyphenon E) in Preventing Cancer in Healthy Participants

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-09-09

Last Posted Date: 2010-01-20

Lead Sponsor: University of Arizona

Registration Number: NCT00091325

Locations: 🇺🇸
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2004-08-03

Last Posted Date: 2013-01-31

Lead Sponsor: University of Arizona

Target Recruit Count: 26

Registration Number: NCT00003415

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Drug/Agent Toxicity by Tissue/Organ

First Posted Date: 2004-08-02

Last Posted Date: 2013-01-31

Lead Sponsor: University of Arizona

Target Recruit Count: 30

Registration Number: NCT00003068

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous/Nonmalignant Condition
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-07-19

Last Posted Date: 2010-03-16

Lead Sponsor: University of Arizona

Target Recruit Count: 27

Registration Number: NCT00003082

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Radiation Toxicity

First Posted Date: 2004-04-14

Last Posted Date: 2010-03-16

Lead Sponsor: University of Arizona

Target Recruit Count: 25

Registration Number: NCT00003307

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

Selenium for Prevention of Adenomatous Colorectal Polyps

Phase 3

Terminated

Conditions: Precancerous Condition
Colorectal Cancer
Adenomatous Colorectal Polyps

Interventions: Drug: Selenium

First Posted Date: 2004-03-09

Last Posted Date: 2019-09-24

Lead Sponsor: University of Arizona

Target Recruit Count: 1621

Registration Number: NCT00078897

Locations: 🇺🇸
Endoscopy Center of Western New York, Williamsville, New York, United States
🇺🇸
Baylor University Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Veterans Affairs Medical Center - Phoenix, Phoenix, Arizona, United States

and more 4 locations

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

Phase 2

Completed

Conditions: Precancerous/Nonmalignant Condition
Non-melanomatous Skin Cancer

First Posted Date: 2004-02-16

Last Posted Date: 2018-09-11

Lead Sponsor: University of Arizona

Registration Number: NCT00021294

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy